Pyrazinamide (PZA)-resistant TB had significantly worse clinical outcomes. The global burden is 1.4 million new PZA-resistant TB cases annually. Unfortunately, there is no reliable PZA susceptibility test available. Accurate and Reliable PZA susceptibility testing Is needed urgently.

Pyrazinamide (PZA) is a first-line tuberculosis drug that plays a unique role in shortening tuberculosis from 9-12 month to 6 months. PZA has no activity at neutral pH in conventional culture media, but at acidic pH 5.0-5.5. PZA susceptibility is notoriously difficult to perform due to the hostile acidic pH that is unfavorable for the growth of Mycobacterium tuberculosis.

PZA innovation LLC is a biotechnology startup company dedicated to developing reliable pyrazinamide, a first-line tuberculosis drug, susceptibility. PZA has sterilizing activity in vivo. Our strategy is to use reverse engineering to find out the conditions under which pyrazinamide is active in vitro, that is, pyrazinamide acts on the living environment of Mycobacterium tuberculosis in the host. We will establish a reliable PZA susceptibility testing method using the condition and develop the next-generation PZA to shorten tuberculosis treatment more even.